Free Twice-Weekly Pharma Manufacturing Newsletter Stay current on Biopharma Packing & Security, Supply Chain Software & Systems, and Contract Manufacturing with a twice-weekly update sent straight to your Inbox. Join more than 30,000 pharma professionals who subscribe to FiercePharmaManufacturing for FREE!
A key element of a plan by KKR to invest in India's Gland Pharma is to boost its manufacturing capacity, and so significantly increase its earnings potential. Citing unnamed sources, The Economic Times said investment firm KKR is looking to take on a 40% share in the small but rapidly growing Gland Pharma in a deal valued at about $500 million. The deal would include the buyout of an existing investor, Evolvence India Life Science Fund, and a cash infusion of between $95 million and $110 million to pump up manufacturing. Story
| Monday, September 14th | 1pm ET / 10am PT | Sponsored by: Elsevier
This webinar will feature experts in drug development, regulatory processes and managed care who can shed light on the impact of escalating drug prices and provide tips on navigating these challenges. Reserve Your Spot Today!
FiercePharmaManufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Click here to get your free twice weekly email briefing today!